Indian pharmaceutical company Jubilant Pharmova posted a reduced fourth-quarter net loss of Rs 5.86 crore compared to Rs 9.79 crore a year ago, bolstered by robust demand for drugs containing radioactive elements. Sales climbed 5% to Rs 1,746 crore, primarily driven by an 18.6% surge in the radiopharma segment, constituting almost half of the revenue. The firm, with 46 radio-pharmacies in the U.S., plans to introduce new products in this sector in the medium term. Revenue from copycat drugs and allergy immunotherapy medicines also saw growth during the quarter. The company declared a dividend of 5 rupees per share, with its shares ending 0.4% higher post-results and showing a 29.5% increase year-to-date.